A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
PSYCHEMEDICS CORP
PMDI
$14M
Mkt Cap
$2.49
+0.00%
PSYCHEMEDICS CORP (PMDI) has a 5-year average return on invested capital (ROIC) of -25.6%. This is below average and may indicate limited pricing power.
PSYCHEMEDICS CORP (PMDI) has a market capitalization of $14M. It is classified as a small-cap stock.
Yes, PSYCHEMEDICS CORP (PMDI) pays a dividend with a trailing twelve-month yield of 5.62%. The company also returns capital through share buybacks, with a buyback yield of 17.70%.
PSYCHEMEDICS CORP (PMDI) operates in the Services-Medical Laboratories industry, within the Healthcare sector.
PSYCHEMEDICS CORP (PMDI) reported annual revenue of $20 million in its most recent fiscal year, based on SEC EDGAR filings.
PSYCHEMEDICS CORP (PMDI) has a net profit margin of -9.5%. The company is currently unprofitable.
PSYCHEMEDICS CORP (PMDI) generated $878 thousand in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Psychemedics Corporation is a Delaware corporation organized on September 24, 1986. All of our physical assets are located within the United States. We provide testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples. Our testing methods utilize a patented technology that digests the hair and releases drugs and substances trapped in the hair without destroying the drugs. This is fundamental to the entire process because the patented method gets virtually 100% of the drug out of the hair. Extracting the drug is an essential prerequisite to measuring it. We then perform a proprietary custom-designed patented enzyme immunoassay (“EIA”) on the liquid supernatant, with confirmation testing by mass spectrometry. Our primary application of our patented technology is as a testing service that analyzes hair samples for the presence of certain drugs of abuse.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 20M | 20M | 22M | 25M | 25M | 21M |
| Net Income | -1.9M | -1.9M | -4.2M | -1.1M | -665K | -3.9M |
| EPS | $-0.32 | $-0.32 | $-0.72 | $-0.19 | $-0.12 | $-0.70 |
| Free Cash Flow | 878K | 878K | -1.6M | 4.7M | 232K | -5.1M |
| ROIC | -38.1% | -36.3% | -59.5% | -9.8% | 1.7% | -24.2% |
| Gross Margin | 36.1% | 36.1% | 38.1% | 36.8% | 41.2% | 22.9% |
| Debt/Equity | 0.04 | 0.04 | 0.09 | 0.08 | 0.10 | 0.33 |
| Dividends/Share | $0.00 | $0.14 | $0.14 | $0.21 | $0.05 | $0.21 |
| Operating Income | -1.9M | -1.9M | -2.9M | -1.1M | 209K | -6.1M |
| Operating Margin | -9.6% | -9.6% | -13.2% | -4.3% | 0.8% | -28.4% |
| ROE | -36.3% | -31.5% | -62.3% | -10.1% | -5.4% | -26.3% |
| Shares Outstanding | 6M | 6M | 6M | 6M | 6M | 5M |
| Metric | 2018 | 2019 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | 27M | 29M | 27M | 39M | 40M | 43M | 38M | 21M | 25M | 25M | 22M | 20M | 20M |
| Gross Margin | 57.3% | 51.8% | 47.1% | 55.0% | 49.9% | 48.3% | 43.6% | 22.9% | 41.2% | 36.8% | 38.1% | 36.1% | 36.1% |
| R&D | 825K | 1.3M | 1.6M | 1.4M | 1.4M | 1.6M | 1.6M | 1.3M | 1.1M | 1.3M | 1.1M | 749K | 749K |
| SG&A | 4.2M | 4.5M | 4.6M | 5.0M | 5.6M | 6.4M | 7.2M | 6.1M | 6.1M | 5.9M | 7.2M | 5.7M | 5.7M |
| EBIT | 5.7M | 4.7M | 1.5M | 10M | 8.2M | 7.6M | 3.0M | -6.1M | 209K | -1.1M | -2.9M | -1.9M | -1.9M |
| Op. Margin | 21.2% | 16.1% | 5.5% | 25.9% | 20.5% | 17.8% | 8.0% | -28.4% | 0.8% | -4.3% | -13.2% | -9.6% | -9.6% |
| Net Income | 3.8M | 3.2M | 1.5M | 6.7M | 6.1M | 4.6M | 1.5M | -3.9M | -665K | -1.1M | -4.2M | -1.9M | -1.9M |
| Net Margin | 14.2% | 11.0% | 5.6% | 17.1% | 15.4% | 10.7% | 4.1% | -18.1% | -2.7% | -4.3% | -18.8% | -9.5% | -9.5% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | -6K | 0 | -94K | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||||||||
| ROIC | 45.1% | 27.3% | 9.7% | 45.2% | 42.3% | 34.8% | 13.4% | -24.2% | 1.7% | -9.8% | -59.5% | -36.3% | -38.1% |
| ROE | 32.4% | 25.5% | 12.3% | 49.0% | 35.8% | 24.5% | 8.7% | -26.3% | -5.4% | -10.1% | -62.3% | -31.5% | -36.3% |
| ROA | 24.8% | 15.8% | 6.6% | 28.4% | 23.8% | 17.8% | 5.9% | -15.0% | -2.9% | -5.8% | -33.7% | -18.0% | -22.4% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | 6.0M | 4.5M | 4.6M | 9.3M | 9.1M | 7.9M | 4.3M | -4.1M | 414K | 4.9M | -1.5M | 929K | 929K |
| Free Cash Flow | 4.4M | -3.1M | 2.8M | 7.3M | 7.9M | 6.7M | 2.6M | -5.1M | 232K | 4.7M | -1.6M | 878K | 878K |
| Owner Earnings | 4.5M | 2.8M | 2.2M | 6.3M | 5.8M | 4.3M | 636K | -22M | -20M | 1.7M | -4.1M | -1.2M | -1.2M |
| CapEx | 1.5M | 7.6M | 1.8M | 2.0M | 1.2M | 1.2M | 1.7M | 991K | 182K | 187K | 157K | 51K | 51K |
| Maint. CapEx | 872K | 1.0M | 1.7M | 2.3M | 2.8M | 3.1M | 2.9M | 17M | 20M | 2.4M | 1.7M | 1.2M | 1.2M |
| Growth CapEx | 659K | 6.5M | 21K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 872K | 1.0M | 1.7M | 2.3M | 2.8M | 3.1M | 2.9M | 17M | 20M | 2.4M | 1.7M | 1.2M | 1.2M |
| CapEx/OCF | 25.7% | 169.7% | 38.3% | 21.7% | 13.1% | 15.0% | 38.9% | N/A | 44.0% | 3.8% | N/A | 5.5% | 5.5% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 3.2M | 3.2M | 3.2M | 3.3M | 3.3M | 3.8M | 4.0M | 993K | 279K | 1.2M | 799K | 0 | 0 |
| Dividend Yield | 7.0% | 5.5% | 5.9% | 4.6% | 3.5% | 4.2% | 7.1% | 3.3% | 0.7% | 3.4% | 3.1% | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.6M | 2.6M |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 18.2% | 17.7% |
| Stock-Based Comp | 538K | 609K | 674K | 671K | 582K | 594K | 759K | 563K | 743K | 872K | 908K | 917K | 917K |
| Debt Repayment | 0 | 700K | 1.5M | 3.1M | 2.1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||||||||
| Net Debt | -4.0M | 2.6M | 3.2M | -557K | -4.8M | -6.3M | -4.7M | 1.3M | -729K | -8.6M | -3.3M | -2.6M | -1.2M |
| Cash & Equiv. | 4.0M | 3.6M | 2.7M | 3.9M | 8.2M | 4.1M | 7.3M | 2.8M | 2.0M | 4.8M | 2.0M | 1.4M | 1.4M |
| Long-Term Debt | 0 | 4.8M | 4.3M | 2.2M | 2.4M | 1.2M | 2.0M | 3.4M | 599K | 305K | 305K | 0 | N/A |
| Debt/Equity | 0.00 | 0.49 | 0.50 | 0.22 | 0.18 | 0.09 | 0.16 | 0.33 | 0.10 | 0.08 | 0.09 | 0.04 | 0.04 |
| Interest Coverage | N/A | 57.3 | 11.4 | 75.4 | 113.3 | 71.8 | 50.8 | -80.9 | 4.3 | -32.8 | -162.3 | -82.3 | -82.3 |
| Equity | 12M | 13M | 12M | 16M | 19M | 19M | 17M | 13M | 12M | 11M | 6.7M | 5.1M | 5.1M |
| Total Assets | 17M | 24M | 22M | 25M | 27M | 25M | 28M | 24M | 22M | 19M | 12M | 8.3M | 8.3M |
| Total Liabilities | 4.3M | 11M | 10M | 9.4M | 7.9M | 6.2M | 11M | 11M | 9.3M | 8.0M | 5.7M | 3.2M | 3.2M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -6.6M | -6.6M | -8.3M | -4.9M | -2.1M | -1.3M | -3.8M | -8.6M | -9.5M | -12M | -17M | -19M | -19M |
| Working Capital | 7.0M | 7.0M | 4.6M | 6.4M | 9.6M | 9.8M | 7.0M | 5.7M | 4.5M | 4.2M | 2.1M | 2.2M | 2.2M |
| Current Assets | 10.0M | 11M | 8.1M | 11M | 14M | 14M | 13M | 9.6M | 10M | 10.0M | 6.8M | 4.9M | 4.9M |
| Current Liabilities | 3.0M | 3.6M | 3.6M | 4.5M | 4.2M | 4.1M | 5.8M | 3.9M | 5.8M | 5.7M | 4.7M | 2.7M | 2.7M |
| Per Share Data | |||||||||||||
| EPS | 0.72 | 0.60 | 0.28 | 1.22 | 1.10 | 0.83 | 0.28 | -0.70 | -0.12 | -0.19 | -0.72 | -0.32 | -0.32 |
| Owner EPS | 0.86 | 0.52 | 0.40 | 1.15 | 1.03 | 0.78 | 0.12 | -3.93 | -3.62 | 0.29 | -0.71 | -0.20 | -0.20 |
| Book Value | 2.32 | 2.40 | 2.16 | 2.85 | 3.35 | 3.41 | 3.07 | 2.28 | 2.22 | 1.90 | 1.16 | 0.88 | 0.88 |
| Cash Flow/Share | 1.13 | 0.83 | 0.85 | 1.69 | 1.64 | 1.44 | 0.79 | -0.74 | 0.08 | 0.86 | -0.26 | 0.16 | -0.12 |
| Dividends/Share | 0.60 | 0.60 | 0.60 | 0.60 | 0.60 | 0.69 | 0.72 | 0.21 | 0.05 | 0.21 | 0.14 | 0.14 | 0.00 |
| Shares Out. | 5.3M | 5.3M | 5.4M | 5.5M | 5.6M | 5.5M | 5.5M | 5.5M | 5.5M | 5.7M | 5.8M | 5.8M | 5.8M |
| Valuation | |||||||||||||
| P/E Ratio | 14.3 | 18.3 | 28.6 | 16.2 | 15.3 | 16.3 | 31.0 | N/A | N/A | N/A | N/A | N/A | -7.8 |
| P/FCF | 12.4 | N/A | 15.4 | 15.0 | 11.8 | 11.1 | 18.1 | N/A | 157.3 | 5.8 | N/A | 15.2 | 16.5 |
| EV/EBIT | 8.8 | 13.1 | 31.5 | 10.7 | 10.9 | 10.0 | 14.4 | N/A | 171.1 | N/A | N/A | N/A | N/A |
| Price/Book | 4.4 | 4.6 | 3.7 | 7.0 | 5.0 | 4.0 | 2.8 | 1.9 | 3.0 | 2.6 | 2.8 | 2.7 | 2.8 |
| Price/Sales | 1.7 | 2.0 | 2.0 | 1.8 | 2.4 | 2.1 | 1.5 | 1.4 | 1.5 | 1.4 | 1.2 | 0.8 | 0.7 |
| FCF Yield | 8.1% | -5.3% | 6.5% | 6.7% | 8.5% | 9.0% | 5.5% | -21.6% | 0.6% | 16.9% | -8.9% | 6.2% | 6.1% |
| Market Cap | 54M | 59M | 43M | 108M | 93M | 75M | 48M | 24M | 36M | 28M | 18M | 14M | 14M |
| Avg. Price | 8.56 | 10.97 | 10.16 | 13.09 | 17.08 | 16.47 | 10.19 | 5.44 | 6.77 | 6.18 | 4.41 | 2.57 | 2.49 |
| Year-End Price | 10.35 | 11.03 | 8.04 | 19.91 | 16.87 | 13.55 | 8.71 | 4.29 | 6.62 | 4.81 | 3.01 | 2.30 | 2.49 |
PSYCHEMEDICS CORP passes 1 of 9 quality checks, indicating weak fundamentals.
On a free-cash-flow basis, the stock trades at 17.3x vs a median of 15.0x. The company's 5-year average gross margin is 35.0%. Total shareholder yield (dividends + buybacks) is 23.3%. At current prices, the estimated annualized return to fair value is -26.3%.
PSYCHEMEDICS CORP (PMDI) has a debt-to-equity ratio of 0.04. This indicates a conservatively financed balance sheet.
PSYCHEMEDICS CORP (PMDI) reported earnings per share (EPS) of $-0.32 in its most recent fiscal year.
PSYCHEMEDICS CORP (PMDI) has a return on equity (ROE) of -31.5%. A negative ROE may indicate losses or negative equity.
PSYCHEMEDICS CORP (PMDI) has a 5-year average gross margin of 35.0%. This indicates decent pricing power.
The Ledger Terminal provides 16 years of financial data for PSYCHEMEDICS CORP (PMDI), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
PSYCHEMEDICS CORP (PMDI) has a book value per share of $0.88, based on its most recent annual SEC filing.
No recent press releases.